Bispecific Proteolytic Antibodies for Treating Alzheimer's

About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
April 01, 2001 - March 31, 2002
Grant ID
A2001043
Summary
It is not yet certain that a vaccine to immunize patients with amyloid beta will be successful in fighting Alzheimer’s disease. One reason is that not everyone who is immunized may produce an immune response. A potential new approach is called passive immunization. In this process, antibodies that bind to amyloid beta would be directly injected into AD patients. Dr. Sierks proposes the additional refinement of introducing an antibody that is genetically engineered to provide two different functions. The first function of the antibody is to bind to amyloid beta. The second function will be to break amyloid beta into two soluble fragments that can be cleared from the brain. Dr. Sierks’ first step in producing such antibodies will be to identify cloned gene sequences of antibodies that will bind to certain regions of the amyloid beta protein. The next step will be to identify antibody sequences that break down the amyloid beta, and to introduce mutations that increase the activity and targeting of the antibody so that it breaks down amyloid beta but not other proteins. Finally, the antibody sequences will be combined into one molecule that can both target and cleave amyloid beta. If this project is successful, the new antibody can be further refined so it can cross the blood-brain barrier, setting the stage for preclinical testing.
Grants
Related Grants
Alzheimer's Disease Research
Tau, Aβ, and Network Degeneration in Alzheimer’s Disease
Active Dates
July 01, 2014 - June 30, 2017
Principal Investigator
Rik Ossenkoppele, PhD
Tau, Aβ, and Network Degeneration in Alzheimer’s Disease
Active Dates
July 01, 2014 - June 30, 2017

Principal Investigator
Rik Ossenkoppele, PhD
Alzheimer's Disease Research
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022
Principal Investigator
Hyunjun Yang, PhD
Fingerprinting In Vivo and In Vitro Prion Strains
Active Dates
September 01, 2020 - November 30, 2022

Principal Investigator
Hyunjun Yang, PhD
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD